Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 119

1.

Loss of Circulating CD8+ CD161high T Cells in Primary Progressive Multiple Sclerosis.

Acquaviva M, Bassani C, Sarno N, Dalla Costa G, Romeo M, Sangalli F, Colombo B, Moiola L, Martinelli V, Comi G, Farina C.

Front Immunol. 2019 Aug 14;10:1922. doi: 10.3389/fimmu.2019.01922. eCollection 2019.

2.

Pharmacokinetics and pharmacodynamics of natalizumab in pediatric patients with RRMS.

Ghezzi A, Comi G, Grimaldi LM, Moiola L, Pozzilli C, Fantaccini S, Gallo P.

Neurol Neuroimmunol Neuroinflamm. 2019 Jul 1;6(5). pii: e591. doi: 10.1212/NXI.0000000000000591. Print 2019 Sep.

3.

Effects of Natalizumab and Fingolimod on Clinical, Cognitive, and Magnetic Resonance Imaging Measures in Multiple Sclerosis.

Preziosa P, Rocca MA, Riccitelli GC, Moiola L, Storelli L, Rodegher M, Comi G, Signori A, Falini A, Filippi M.

Neurotherapeutics. 2019 Aug 26. doi: 10.1007/s13311-019-00781-w. [Epub ahead of print]

PMID:
31452082
4.

Subclinical neurodegeneration in multiple sclerosis and neuromyelitis optica spectrum disorder revealed by optical coherence tomography.

Pisa M, Ratti F, Vabanesi M, Radaelli M, Guerrieri S, Moiola L, Martinelli V, Comi G, Leocani L.

Mult Scler. 2019 Aug 8:1352458519861603. doi: 10.1177/1352458519861603. [Epub ahead of print]

PMID:
31392924
5.

Performance of SLE responder index and lupus low disease activity state in real life: A prospective cohort study.

Ramirez GA, Canti V, Moiola L, Magnoni M, Rovere-Querini P, Coletto LA, Dagna L, Manfredi AA, Bozzolo EP.

Int J Rheum Dis. 2019 Sep;22(9):1752-1761. doi: 10.1111/1756-185X.13663. Epub 2019 Aug 5.

PMID:
31379114
6.

Pharmacokinetics and pharmacodynamics of natalizumab in pediatric patients with RRMS.

Ghezzi A, Comi G, Grimaldi LM, Moiola L, Pozzilli C, Fantaccini S, Gallo P.

Neurol Neuroimmunol Neuroinflamm. 2019 Jul 1;6(5):e591. doi: 10.1212/NXI.0000000000000591. eCollection 2019 Sep.

7.

In vivo structural and functional assessment of optic nerve damage in neuromyelitis optica spectrum disorders and multiple sclerosis.

Vabanesi M, Pisa M, Guerrieri S, Moiola L, Radaelli M, Medaglini S, Martinelli V, Comi G, Leocani L.

Sci Rep. 2019 Jul 17;9(1):10371. doi: 10.1038/s41598-019-46251-3.

8.

Structural and functional brain connectomes in patients with systemic lupus erythematosus.

Preziosa P, Rocca MA, Ramirez GA, Bozzolo EP, Canti V, Pagani E, Valsasina P, Moiola L, Rovere-Querini P, Manfredi AA, Filippi M.

Eur J Neurol. 2019 Jul 15. doi: 10.1111/ene.14041. [Epub ahead of print]

PMID:
31306535
9.

Caesarean section and infant formula feeding are associated with an earlier age of onset of multiple sclerosis.

Dalla Costa G, Romeo M, Esposito F, Sangalli F, Colombo B, Radaelli M, Moiola L, Comi G, Martinelli V.

Mult Scler Relat Disord. 2019 Aug;33:75-77. doi: 10.1016/j.msard.2019.05.010. Epub 2019 May 21.

PMID:
31158806
10.

Dynamic gray matter volume changes in pediatric multiple sclerosis: A 3.5 year MRI study.

De Meo E, Meani A, Moiola L, Ghezzi A, Veggiotti P, Filippi M, Rocca MA.

Neurology. 2019 Apr 9;92(15):e1709-e1723. doi: 10.1212/WNL.0000000000007267. Epub 2019 Mar 13.

PMID:
30867274
11.

Serum neurofilaments increase at progressive multifocal leukoencephalopathy onset in natalizumab-treated multiple sclerosis patients.

Dalla Costa G, Martinelli V, Moiola L, Sangalli F, Colombo B, Finardi A, Cinque P, Kolb EM, Haghikia A, Gold R, Furlan R, Comi G.

Ann Neurol. 2019 Apr;85(4):606-610. doi: 10.1002/ana.25437. Epub 2019 Mar 5.

PMID:
30761586
12.

Prognostic value of serum neurofilaments in patients with clinically isolated syndromes.

Dalla Costa G, Martinelli V, Sangalli F, Moiola L, Colombo B, Radaelli M, Leocani L, Furlan R, Comi G.

Neurology. 2019 Feb 12;92(7):e733-e741. doi: 10.1212/WNL.0000000000006902. Epub 2019 Jan 11.

13.

Severe disease activity in a patient with multiple sclerosis after daclizumab discontinuation.

Martinelli V, Dalla Costa G, Sangalli F, Colombo B, Robotti M, Moiola L, Comi G.

Mult Scler Relat Disord. 2019 Feb;28:57-59. doi: 10.1016/j.msard.2018.11.034. Epub 2018 Dec 1.

PMID:
30554038
14.

Acquired haemophilia A as a secondary autoimmune disease after alemtuzumab treatment in multiple sclerosis: A case report.

Pisa M, Della Valle P, Coluccia A, Martinelli V, Comi G, D'Angelo A, Moiola L.

Mult Scler Relat Disord. 2019 Jan;27:403-405. doi: 10.1016/j.msard.2018.11.029. Epub 2018 Nov 29.

PMID:
30513503
15.

No evidence of disease activity (NEDA-3) and disability improvement after alemtuzumab treatment for multiple sclerosis: a 36-month real-world study.

Prosperini L, Annovazzi P, Boffa L, Buscarinu MC, Gallo A, Matta M, Moiola L, Musu L, Perini P, Avolio C, Barcella V, Bianco A, Farina D, Ferraro E, Pontecorvo S, Granella F, Grimaldi LME, Laroni A, Lus G, Patti F, Pucci E, Pasca M, Sarchielli P; Italian Alemtuzumab Study Group.

J Neurol. 2018 Dec;265(12):2851-2860. doi: 10.1007/s00415-018-9070-x. Epub 2018 Sep 26.

PMID:
30259178
16.

Assessing the role of innovative therapeutic paradigm on multiple sclerosis treatment response.

Romeo MAL, Martinelli V, Dalla Costa G, Colombo B, De Feo D, Esposito F, Ferrè L, Guaschino C, Guerrieri S, Liberatore G, Martinelli Boneschi F, Merlini A, Messina M, Messina R, Nuara A, Preziosa P, Radaelli M, Rocca MA, Rodegher M, Sangalli F, Strambo D, Moiola L, Comi G.

Acta Neurol Scand. 2018 Nov;138(5):447-453. doi: 10.1111/ane.12999. Epub 2018 Jul 22.

PMID:
30033621
17.

Basal vitamin D levels and disease activity in multiple sclerosis patients treated with fingolimod.

Ferre' L, Clarelli F, Sferruzza G, Rocca MA, Mascia E, Radaelli M, Sangalli F, Dalla Costa G, Moiola L, Aboulwafa M, Martinelli Boneschi F, Comi G, Filippi M, Martinelli V, Esposito F.

Neurol Sci. 2018 Aug;39(8):1467-1470. doi: 10.1007/s10072-018-3440-0. Epub 2018 May 13.

PMID:
29756179
18.

Pregnancy decision-making in women with multiple sclerosis treated with natalizumab: I: Fetal risks.

Portaccio E, Annovazzi P, Ghezzi A, Zaffaroni M, Moiola L, Martinelli V, Lanzillo R, Brescia Morra V, Rinaldi F, Gallo P, Tortorella C, Paolicelli D, Pozzilli C, De Giglio L, Cavalla P, Cocco E, Marrosu MG, Patti F, Solaro C, Bellantonio P, Uccelli A, Laroni A, Pastò L, Giannini M, Trojano M, Comi G, Amato MP; MS Study Group of the Italian Neurological Society.

Neurology. 2018 Mar 6;90(10):e823-e831. doi: 10.1212/WNL.0000000000005067. Epub 2018 Feb 7.

PMID:
29438046
19.

Pregnancy decision-making in women with multiple sclerosis treated with natalizumab: II: Maternal risks.

Portaccio E, Moiola L, Martinelli V, Annovazzi P, Ghezzi A, Zaffaroni M, Lanzillo R, Brescia Morra V, Rinaldi F, Gallo P, Tortorella C, Paolicelli D, Pozzilli C, De Giglio L, Cavalla P, Cocco E, Marrosu MG, Solaro C, Uccelli A, Laroni A, Pastò L, Giannini M, Trojano M, Comi G, Amato MP; MS Study Group of the Italian Neurological Society.

Neurology. 2018 Mar 6;90(10):e832-e839. doi: 10.1212/WNL.0000000000005068. Epub 2018 Feb 7.

PMID:
29438041
20.

Effectiveness and baseline factors associated to fingolimod response in a real-world study on multiple sclerosis patients.

Esposito F, Ferrè L, Clarelli F, Rocca MA, Sferruzza G, Storelli L, Radaelli M, Sangalli F, Moiola L, Colombo B, Martinelli Boneschi F, Comi G, Filippi M, Martinelli V.

J Neurol. 2018 Apr;265(4):896-905. doi: 10.1007/s00415-018-8791-1. Epub 2018 Feb 12.

PMID:
29435643
21.

Long-term follow-up of pediatric MS patients starting treatment with injectable first-line agents: A multicentre, Italian, retrospective, observational study.

Baroncini D, Zaffaroni M, Moiola L, Lorefice L, Fenu G, Iaffaldano P, Simone M, Fanelli F, Patti F, D'Amico E, Capobianco M, Bertolotto A, Gallo P, Margoni M, Miante S, Milani N, Amato MP, Righini I, Bellantonio P, Scandellari C, Costantino G, Scarpini E, Bergamaschi R, Mallucci G, Comi G, Ghezzi A.

Mult Scler. 2019 Mar;25(3):399-407. doi: 10.1177/1352458518754364. Epub 2018 Jan 24. Erratum in: Mult Scler. 2019 Oct;25(11):NP33.

PMID:
29363396
22.

Necrotic-hemorrhagic myelitis: A rare malignant variant of parainfectious acute disseminated encephalomyelitis in childhood.

Preziosa P, Moiola L, Baldoli C, Longo D, Sangalli F, Radaelli M, Comi G, Martinelli V, Filippi M.

J Neurol Sci. 2018 Jan 15;384:58-60. doi: 10.1016/j.jns.2017.11.032. Epub 2017 Nov 23. No abstract available.

PMID:
29249379
23.

Smart watch, smarter EDSS: Improving disability assessment in multiple sclerosis clinical practice.

Dalla-Costa G, Radaelli M, Maida S, Sangalli F, Colombo B, Moiola L, Comi G, Martinelli V.

J Neurol Sci. 2017 Dec 15;383:166-168. doi: 10.1016/j.jns.2017.10.043. Epub 2017 Oct 27.

PMID:
29246607
24.

No evidence of disease activity is associated with reduced rate of axonal retinal atrophy in MS.

Pisa M, Guerrieri S, Di Maggio G, Medaglini S, Moiola L, Martinelli V, Comi G, Leocani L.

Neurology. 2017 Dec 12;89(24):2469-2475. doi: 10.1212/WNL.0000000000004736. Epub 2017 Nov 15.

PMID:
29142087
25.

To do or not to do? plasma exchange and timing of steroid administration in progressive multifocal leukoencephalopathy.

Scarpazza C, Prosperini L, De Rossi N, Moiola L, Sormani MP, Gerevini S, Capra R; Italian PML group.

Ann Neurol. 2017 Nov;82(5):697-705. doi: 10.1002/ana.25070. Epub 2017 Oct 31.

PMID:
29023856
26.

Corrigendum to "Is maraviroc useful in multiple sclerosis patients with natalizumab-related progressive multifocal leukoencephalopathy?" [J. Neurol. Sci. 378 (2017) 233-237].

Scarpazza C, Prosperini L, Mancinelli CR, De Rossi N, Lugaresi A, Capobianco M, Moiola L, Naldi P, Imberti L, Gerevini S, Capra R.

J Neurol Sci. 2017 Sep 15;380:19. doi: 10.1016/j.jns.2017.06.037. Epub 2017 Jul 4. No abstract available.

PMID:
28870565
27.

MRI substrates of sustained attention system and cognitive impairment in pediatric MS patients.

De Meo E, Moiola L, Ghezzi A, Veggiotti P, Capra R, Amato MP, Pagani E, Fiorino A, Pippolo L, Pera MC, Comi G, Falini A, Filippi M, Rocca MA.

Neurology. 2017 Sep 19;89(12):1265-1273. doi: 10.1212/WNL.0000000000004388. Epub 2017 Aug 18.

28.

Is maraviroc useful in multiple sclerosis patients with natalizumab-related progressive multifocal leukoencephalopathy?

Scarpazza C, Prosperini L, Mancinelli CR, De Rossi N, Lugaresi A, Capobianco M, Moiola L, Naldi P, Imberti L, Gerevini S, Capra R.

J Neurol Sci. 2017 Jul 15;378:233-237. doi: 10.1016/j.jns.2017.05.018. Epub 2017 May 12. Erratum in: J Neurol Sci. 2017 Sep 15;380:19.

PMID:
28566170
29.

Multiple biomarkers improve the prediction of multiple sclerosis in clinically isolated syndromes.

Martinelli V, Dalla Costa G, Messina MJ, Di Maggio G, Sangalli F, Moiola L, Rodegher M, Colombo B, Furlan R, Leocani L, Falini A, Comi G.

Acta Neurol Scand. 2017 Nov;136(5):454-461. doi: 10.1111/ane.12761. Epub 2017 Apr 9.

PMID:
28393349
30.

Dysregulation of MS risk genes and pathways at distinct stages of disease.

Srinivasan S, Di Dario M, Russo A, Menon R, Brini E, Romeo M, Sangalli F, Costa GD, Rodegher M, Radaelli M, Moiola L, Cantarella D, Medico E, Martino G, Furlan R, Martinelli V, Comi G, Farina C.

Neurol Neuroimmunol Neuroinflamm. 2017 Mar 16;4(3):e337. doi: 10.1212/NXI.0000000000000337. eCollection 2017 May.

31.

Moyamoya disease mimicking the first attack of multiple sclerosis.

Preziosa P, Martinelli V, Ferrè L, Guaschino C, Simionato F, Moiola L, Comi G, Filippi M.

J Neurol. 2017 May;264(5):1005-1007. doi: 10.1007/s00415-017-8458-3. Epub 2017 Mar 17. No abstract available.

PMID:
28314979
32.

Half-dose fingolimod for treating relapsing-remitting multiple sclerosis: Observational study.

Zecca C, Merlini A, Disanto G, Rodegher M, Panicari L, Romeo MAL, Candrian U, Messina MJ, Pravatà E, Moiola L, Stefanin C, Ghezzi A, Perrone P, Patti F, Comi G, Gobbi C, Martinelli V.

Mult Scler. 2018 Feb;24(2):167-174. doi: 10.1177/1352458517694089. Epub 2017 Feb 1.

PMID:
28273776
33.

Free Light Chains and Intrathecal B Cells Activity in Multiple Sclerosis: A Prospective Study and Meta-Analysis.

Passerini G, Dalla Costa G, Sangalli F, Moiola L, Colombo B, Locatelli M, Comi G, Furlan R, Martinelli V.

Mult Scler Int. 2016;2016:2303857. doi: 10.1155/2016/2303857. Epub 2016 Dec 28.

34.

Natalizumab-Related Progressive Multifocal Leukoencephalopathy in Multiple Sclerosis: Findings from an Italian Independent Registry.

Prosperini L, de Rossi N, Scarpazza C, Moiola L, Cosottini M, Gerevini S, Capra R; Italian PML study group.

PLoS One. 2016 Dec 20;11(12):e0168376. doi: 10.1371/journal.pone.0168376. eCollection 2016.

35.

Alemtuzumab Use in Clinical Practice: Recommendations from European Multiple Sclerosis Experts.

Berger T, Elovaara I, Fredrikson S, McGuigan C, Moiola L, Myhr KM, Oreja-Guevara C, Stoliarov I, Zettl UK.

CNS Drugs. 2017 Jan;31(1):33-50. doi: 10.1007/s40263-016-0394-8. Review.

36.

Clinical deterioration due to co-occurrence of multiple sclerosis and glioblastoma: report of two cases.

Preziosa P, Sangalli F, Esposito F, Moiola L, Martinelli V, Falini A, Comi G, Filippi M.

Neurol Sci. 2017 Feb;38(2):361-364. doi: 10.1007/s10072-016-2763-y. Epub 2016 Nov 11.

PMID:
27837369
37.

Rituximab in the treatment of Neuromyelitis optica: a multicentre Italian observational study.

Annovazzi P, Capobianco M, Moiola L, Patti F, Frau J, Uccelli A, Centonze D, Perini P, Tortorella C, Prosperini L, Lus G, Fuiani A, Falcini M, Martinelli V, Comi G, Ghezzi A.

J Neurol. 2016 Sep;263(9):1727-35. doi: 10.1007/s00415-016-8188-y. Epub 2016 Jun 10.

PMID:
27286847
38.

Progressive ataxia in a natalizumab-treated multiple sclerosis patient: the dark side of JC virus infection.

Martinelli V, Dalla Costa G, Moiola L, Pavan G, Diotti RA, De Riz MA, Gerevini S, Comi G.

Eur J Neurol. 2016 Jul;23(7):e39-40. doi: 10.1111/ene.13027. No abstract available.

PMID:
27272110
39.

Natalizumab versus fingolimod in patients with relapsing-remitting multiple sclerosis non-responding to first-line injectable therapies.

Baroncini D, Ghezzi A, Annovazzi PO, Colombo B, Martinelli V, Minonzio G, Moiola L, Rodegher M, Zaffaroni M, Comi G.

Mult Scler. 2016 Sep;22(10):1315-26. doi: 10.1177/1352458516650736. Epub 2016 May 26.

PMID:
27230789
40.

Divergent Trends of Anti-JCPyV Serum Reactivity and Neutralizing Activity in Multiple Sclerosis (MS) Patients during Treatment with Natalizumab.

Diotti RA, Capra R, Moiola L, Caputo V, De Rossi N, Sangalli F, Martinelli V, Burioni R, Clementi M, Mancini N.

Viruses. 2016 May 7;8(5). pii: E128. doi: 10.3390/v8050128.

41.

Exploratory analysis of predictors of patient adherence to subcutaneous interferon beta-1a in multiple sclerosis: TRACER study.

Paolicelli D, Cocco E, Di Lecce V, Direnzo V, Moiola L, Lanzillo R, Perini P, Malucchi S, Borriello G, Portaccio E, Panetta V, Fenu G, Sangalli F, Cacciaguerra L, Trojano M; TRACER Group.

Expert Opin Drug Deliv. 2016 Jun;13(6):799-805. doi: 10.1517/17425247.2016.1158161. Epub 2016 Mar 12.

PMID:
26922837
42.

The cognitive reserve theory in the setting of pediatric-onset multiple sclerosis.

Pastò L, Portaccio E, Goretti B, Ghezzi A, Lori S, Hakiki B, Giannini M, Righini I, Razzolini L, Niccolai C, Moiola L, Falautano M, Simone M, Viterbo RG, Patti F, Cilia S, Pozzilli C, Bianchi V, Roscio M, Martinelli V, Comi G, Trojano M, Amato MP; MS Study Group of the Italian Neurological Society.

Mult Scler. 2016 Nov;22(13):1741-1749. Epub 2016 Feb 11.

PMID:
26869527
43.

Dynamic pattern of clinical and MRI findings in a tumefactive demyelinating lesion: A case report.

Preziosa P, Martinelli V, Moiola L, Radaelli M, Gerevini S, Guidetti D, Immovilli P, Michieletti E, Scagnelli P, Comola M, Rocca MA, Filippi M, Comi G.

J Neurol Sci. 2016 Feb 15;361:184-6. doi: 10.1016/j.jns.2015.12.039. Epub 2015 Dec 28. No abstract available.

PMID:
26810538
44.

The Communication of Multiple Sclerosis Diagnosis: The Patients' Perspective.

Messina MJ, Dalla Costa G, Rodegher M, Moiola L, Colombo B, Comi G, Martinelli V.

Mult Scler Int. 2015;2015:353828. doi: 10.1155/2015/353828. Epub 2015 Dec 15.

45.

Pharmacogenetic study of long-term response to interferon-β treatment in multiple sclerosis.

Clarelli F, Liberatore G, Sorosina M, Osiceanu AM, Esposito F, Mascia E, Santoro S, Pavan G, Colombo B, Moiola L, Martinelli V, Comi G, Martinelli-Boneschi F.

Pharmacogenomics J. 2017 Jan;17(1):84-91. doi: 10.1038/tpj.2015.85. Epub 2015 Dec 8.

PMID:
26644207
46.

Clinical significance of the number of oligoclonal bands in patients with clinically isolated syndromes.

Dalla Costa G, Passerini G, Messina MJ, Moiola L, Rodegher M, Colombo B, Locatelli M, Comi G, Furlan R, Martinelli V.

J Neuroimmunol. 2015 Dec 15;289:62-7. doi: 10.1016/j.jneuroim.2015.10.009. Epub 2015 Oct 19.

PMID:
26616872
47.

Myeloid cells as target of fingolimod action in multiple sclerosis.

Di Dario M, Colombo E, Govi C, De Feo D, Messina MJ, Romeo M, Sangalli F, Moiola L, Rodegher M, Martino G, Martinelli V, Comi G, Farina C.

Neurol Neuroimmunol Neuroinflamm. 2015 Nov 4;2(6):e157. doi: 10.1212/NXI.0000000000000157. eCollection 2015 Dec.

48.

Efficacy and safety of nabiximols (Sativex(®)) on multiple sclerosis spasticity in a real-life Italian monocentric study.

Ferrè L, Nuara A, Pavan G, Radaelli M, Moiola L, Rodegher M, Colombo B, Keller Sarmiento IJ, Martinelli V, Leocani L, Martinelli Boneschi F, Comi G, Esposito F.

Neurol Sci. 2016 Feb;37(2):235-42. doi: 10.1007/s10072-015-2392-x. Epub 2015 Oct 16.

PMID:
26474875
49.

Natalizumab in the pediatric MS population: results of the Italian registry.

Ghezzi A, Moiola L, Pozzilli C, Brescia-Morra V, Gallo P, Grimaldi LM, Filippi M, G GC; MS Study Group-Italian Society of Neurology.

BMC Neurol. 2015 Sep 25;15:174. doi: 10.1186/s12883-015-0433-y.

50.

Regional hippocampal involvement and cognitive impairment in pediatric multiple sclerosis.

Rocca MA, Morelli ME, Amato MP, Moiola L, Ghezzi A, Veggiotti P, Capra R, Pagani E, Portaccio E, Fiorino A, Pippolo L, Pera MC, Comi G, Falini A, Filippi M.

Mult Scler. 2016 Apr;22(5):628-40. doi: 10.1177/1352458515598569. Epub 2015 Aug 18.

PMID:
26286701

Supplemental Content

Loading ...
Support Center